Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Open-Label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis

Next Previous
Search
Trial Profile

Phase II Open-Label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raltegravir (Primary) ; Efavirenz; Entecavir; Lamivudine; Rifampicin; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms REFLATE TB

    • Most Recent Events

    • 07 Mar 2018 Results (n=153) assessing effects of efavirenz or raltegravir regimens on inflammation and coagulation biomarkers levels up to 48 weeks after ART initiation, in HIV-1 and TB co-infected individuals, were presented at the 25th Conference on Retroviruses and Opportunistic Infections.
    • 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
    • 06 Mar 2013 48-week results presented at the 20th Conference on Retroviruses and Opportunistic Infections.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top